US EditionNovo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera
Novo Nordisk's $6.5 billion upfront bid for Metsera includes milestone payments and challenges Pfizer's $4.9 billion offer amid a fast-growing $150 billion obesity drug market.
- Novo Nordisk launched a rival bid of up to $8.5 billion for U.S. biotech firm Metsera, hijacking an offer from Pfizer worth $7.3 billion.
- Pfizer said Novo Nordisk's bid was "reckless" and would be bad for competition in the obesity drug market.
- Novo Nordisk's move signals an aggressive turn after concerns it was not moving fast enough in the obesity market, where it competes with Eli Lilly.
42 Articles
42 Articles
Denmark's Novo Nordisk in bidding war with US rival Pfizer
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, has announced an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move "reckless".
Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera
Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash. The post Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera appeared first on MedCity News.
Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition
Novo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc. Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases. In an Oct. 30 statement, Novo Nordisk confirmed it had submitted an unsolicited proposal to acquire Metsera. The company stated that the acquisition would complement its goals of develop…
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Metsera (NASDAQ:MTSR), Novo Nordisk (NYSE:NVO), Pfizer (NYSE:PFE)
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO). Metsera said the proposal constitutes a “Superior Company Proposal” as defined in Metsera’s existing Merger Agreement with Pfizer Inc (NYSE:PFE). In September, Pfizer agreed to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion. The acquisition brings a portfolio of diffe…
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
